Literature DB >> 24989847

No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer.

K Boehm1, B Beyer, P Tennstedt, J Schiffmann, L Budaeus, A Haese, M Graefen, T Schlomm, H Heinzer, G Salomon.   

Abstract

PURPOSE: To assess the association between blood loss, blood transfusion (BT) and biochemical recurrence (BCR)-free, metastasis-free and overall survival after radical prostatectomy (RP) in a large single-center cohort of patients. Perioperative BT at oncologic surgery has been reported to be a potential risk factor for cancer recurrence and survival in several cancer entities. Current studies addressing the relationship between BT, blood loss and BCR-free survival in prostate cancer patients are controversial and include only series with fairly small patient cohorts.
MATERIALS AND METHODS: The data of 11,723 patients who underwent RP between 01/1992 and 08/2011 were analyzed. Cox regression analysis, including preoperative PSA level, pT stage, lymph node status, Gleason score, margin status, blood loss, transfusion rate (allogeneic or autologous), tested the relationship between blood loss, transfusion and BCR-free, metastasis-free and overall survival. Additionally, propensity score-matching analysis was performed to adjust differences in tumor characteristics.
RESULTS: There was no statistically significant relationship between blood loss or BT and BCR-free, metastasis-free or overall survival. In multivariate analysis PSA level, pT stage, Gleason score, margin status and lymph node status were independent factors for a BCR (p < 0.0001). These results were identical after propensity score matching analysis, comparing patients with and without BT.
CONCLUSIONS: This large-scale analysis revealed no correlation between blood loss, blood transfusion and oncological outcome in prostate cancer patients treated with RP. Therefore, the association between higher blood loss or transfusion rate and cancer recurrence as described in other surgical treated tumor entities seems to be irrelevant in prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24989847     DOI: 10.1007/s00345-014-1351-0

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

Review 1.  Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy.

Authors:  Ashutosh Tewari; Prasanna Sooriakumaran; Daniel A Bloch; Usha Seshadri-Kreaden; April E Hebert; Peter Wiklund
Journal:  Eur Urol       Date:  2012-02-24       Impact factor: 20.096

Review 2.  Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention.

Authors:  Eleftherios C Vamvakas; Morris A Blajchman
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

Review 3.  Immunomodulation by blood transfusion: an evolving scientific and clinical challenge.

Authors:  N Blumberg; J M Heal
Journal:  Am J Med       Date:  1996-09       Impact factor: 4.965

4.  Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base.

Authors:  Joseph L Chin; John Srigley; Linda A Mayhew; R Bryan Rumble; Claire Crossley; Amber Hunter; Neil Fleshner; Bish Bora; Robin McLeod; Sheila McNair; Bernard Langer; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2010-02       Impact factor: 1.862

5.  Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy.

Authors:  Andrea Gallina; Alberto Briganti; Felix K-H Chun; Jochen Walz; Georg C Hutterer; Andreas Erbersdobler; Christian Eichelberg; Thorsten Schlomm; Sascha A Ahyai; Paul Perrotte; Fred Saad; Francesco Montorsi; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2007-09-10       Impact factor: 5.588

6.  Effect of perioperative blood transfusion on prostate cancer recurrence.

Authors:  Beneranda S Ford; Satish Sharma; Hamed Rezaishiraz; Robert S Huben; James L Mohler
Journal:  Urol Oncol       Date:  2007-11-07       Impact factor: 3.498

Review 7.  Transfusion immunomodulation--the case for leukoreduced and (perhaps) washed transfusions.

Authors:  Katie L Lannan; Julie Sahler; Sherry L Spinelli; Richard P Phipps; Neil Blumberg
Journal:  Blood Cells Mol Dis       Date:  2012-09-13       Impact factor: 3.039

8.  Current technique of open intrafascial nerve-sparing retropubic prostatectomy.

Authors:  Lars Budäus; Hendrik Isbarn; Thorsten Schlomm; Hans Heinzer; Alexander Haese; Thomas Steuber; Georg Salomon; Hartwig Huland; Markus Graefen
Journal:  Eur Urol       Date:  2009-05-29       Impact factor: 20.096

Review 9.  Perioperative immunosuppression in cancer patients.

Authors:  Ricardo Vallejo; E Daniela Hord; Steven A Barna; Juan Santiago-Palma; Shihab Ahmed
Journal:  J Environ Pathol Toxicol Oncol       Date:  2003       Impact factor: 3.567

Review 10.  Perioperative blood transfusions for the recurrence of colorectal cancer.

Authors:  A Amato; M Pescatori
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25
View more
  13 in total

1.  Perioperative blood transfusion as a poor prognostic factor after aggressive surgical resection for hilar cholangiocarcinoma.

Authors:  Norihisa Kimura; Yoshikazu Toyoki; Keinosuke Ishido; Daisuke Kudo; Yuta Yakoshi; Shinji Tsutsumi; Takuya Miura; Taiichi Wakiya; Kenichi Hakamada
Journal:  J Gastrointest Surg       Date:  2015-04-21       Impact factor: 3.452

2.  Perioperative blood transfusion and long-term outcomes after resection of hilar cholangiocarcinoma.

Authors:  Yi-Nan Shen; Han Zhang; Jun-Hua Lu; Myron E Schwartz; Tian Yang
Journal:  J Gastrointest Surg       Date:  2015-04-21       Impact factor: 3.452

3.  Blood transfusion and postoperative complications: a cautionary comment.

Authors:  Jian-Hong Zhong; Bang-De Xiang; Le-Qun Li
Journal:  Transl Gastroenterol Hepatol       Date:  2016-07-18

Review 4.  Perioperative Blood Transfusion Promotes Worse Outcomes of Bladder Cancer after Radical Cystectomy: A Systematic Review and Meta-Analysis.

Authors:  You-Lin Wang; Bo Jiang; Fu-Fen Yin; Hao-Qing Shi; Xiao-Dong Xu; Shuai-Shuai Zheng; Shuai Wu; Si-Chuan Hou
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

5.  The prognostic impact of perioperative blood transfusion on survival in patients with bladder urothelial carcinoma treated with radical cystectomy.

Authors:  Joong Sub Lee; Hyung Suk Kim; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Korean J Urol       Date:  2015-03-26

Review 6.  Blood transfusion practices in cancer surgery.

Authors:  Juan P Cata; Vijaya Gottumukkala
Journal:  Indian J Anaesth       Date:  2014-09

7.  Perioperative Blood Transfusion as a Significant Predictor of Biochemical Recurrence and Survival after Radical Prostatectomy in Patients with Prostate Cancer.

Authors:  Jung Kwon Kim; Hyung Suk Kim; Juhyun Park; Chang Wook Jeong; Ja Hyeon Ku; Hyun Hoe Kim; Cheol Kwak
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

Review 8.  Association between Allogeneic or Autologous Blood Transfusion and Survival in Patients after Radical Prostatectomy: A Systematic Review and Meta-Analysis.

Authors:  Su-Liang Li; Yun Ye; Xiao-Hua Yuan
Journal:  PLoS One       Date:  2017-01-30       Impact factor: 3.240

9.  Effect of Local Fibrinogen Administration on Postoperative Bleeding in Open Prostatectomy Surgery.

Authors:  Farahzad Janatmakan; Nozar Nassajian; Mohsen Sarkarian; Mohammadreza Ghandizadeh Dezfuli; Amir Salari; Seyed Kamaleddin Tabatabaei; Farhad Soltani; Sheida Nassajian
Journal:  Anesth Pain Med       Date:  2018-06-29

10.  Peri-Operative Blood Transfusion Does Not Influence Overall and Disease-Free Survival After Radical Gastrectomy for Stage II/III Gastric Cancer: a Propensity Score Matching Analysis.

Authors:  Hua Xiao; Wu Liu; Hu Quan; Yongzhong Ouyang
Journal:  J Gastrointest Surg       Date:  2018-05-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.